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Reply from the Authors
We thank Hilbrands et al for their letter responding
to the recent papers by de Jong and Brenner [1] and de
Zeeuw [2].
In the first paper, we emphasized that we should not
only pay attention to the classic proteinuria as a mani-
festation of overt renal disease, but should now also fo-
cus on the detection of subjects with microalbuminuria,
even outside the context of diabetes. These latter patients,
mostly with still normal renal function, normally do not
come to the attention of the nephrologist, as they thus
far were not diagnosed. In that first paper, we expressed
the hope that the review would spur others to augment
the level of dialogue and to carry out epidemiologic and
clinical outcome studies [1].
In the second paper, we concluded that future trials, in
addition to the one published by Asselbergs et al, may
provide us with the data that ensure that albuminuria
should be measured and that, in case of abnormal high
albumin levels, treatment should be initiated to lower al-
buminuria [2]. Only the results of such trials may help
to prove that albuminuria (just as blood pressure and
plasma cholesterol) should be targeted to obtain cardiac
and renal protection in the general population, as has
been shown for diabetics.
As Hilbrands et al point out correctly, Remuzzi and
Weening found the evidence already that screening of
the population should be advocated [3], and Ritz recently
concluded that we have entered an era in which treating
microalbuminuria is no longer just a cosmetic exercise
with urine chemistry, but an approach resulting in reduc-
tion of clinical events [4].
We are happy that Hilbrands et al opened the dia-
logue requested for. However, they in fact seem to chal-
lenge not the concept, but only the fact that we, among
others, cited Asselbergs’ paper, recently published in
Circulation, by raising various questions regarding the
validity and interpretation of that data. The paper shows
that fosinopril lowers albuminuria by around 30% dur-
ing 4 years in a group of patients with an albuminuria
of 15 to 300 mg/day and a blood pressure <160/100 mm
Hg and a plasma cholesterol of <8.0 mmol/L, or <5.0
in case of a previous myocardial infarction. This lower-
ing of albuminuria was associated with an, albeit statisti-
cally insignificant, fall in the incidence of cardiovascular
events of 40% (P = 0.098). It is surprising that Hilbrands
et al have not submitted these questions to Circulation
because that would have given Asselbergs et al the op-
portunity to answer in detail. We concluded from the
Circulation paper that the PREVEND intervention trial
is hypothesis generating and did not generate a definite
answer on the question whether primary prevention is in-
dicated in microalbuminuric subjects without any other
indication for primary prevention. We emphasized that
other, larger studies still should be performed.
Hilbrands et al argue that the beneficial renal and car-
diovascular effects of RAS-blockade in albuminuric sub-
jects thus far have only been proven for type 2 diabet-
ics. We would, however, mention that many studies, also
including nondiabetic subjects, have shown that albumin-
uria is a risk marker, and that the individuals with albu-
minuria have the most benefit of treatment in large, hard
end point trials like HOPE and LIFE. In the HOPE study
it has been shown that the reduction in CV end points by
the ACE inhibitor ramipril was greater in the subjects
with higher baseline values of albuminuria [6]. A similar
observation was done in the LIFE study, which led the
authors to conclude that part of the mechanism behind
the superiority of the angiotensin II antagonist losartan
to lower the incidence of CV end points was related to
its greater effect on reducing albuminuria [7]. In a recent
report these authors moreover showed that the albumin-
uria during treatment predicts CV outcome better than
blood pressure during treatment [8].
We thus hope that based upon these dialogues, the en-
deavours to start a large intervention trial that targets al-
buminuria to prevent cardiovascular and renal outcomes
will be successful.
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Diaphragmed fenestrae in the
glomerular endothelium versus
nondiaphragmed fenestrae in
the hepatic endothelium
To the Editor: In a recent issue of Kidney Interna-
tional, Ballermann [1] discussed the development of
diaphragmed fenestrae in glomerular endothelial cells.
Major similarities exist between the hepatic and the
glomerular endothelium regarding the process of fen-
estrae formation; intriguingly, an analogous controversy
about the origin of fenestrae exists in both the hepatology
and nephrology fields [2].
Hepatic endothelial fenestrae are dynamic structures
that act as a sieving barrier to control the extensive
exchange of material between the blood and the liver
parenchyma. These membrane-bound pores lack a di-
aphragm and a basal lamina is also absent (Fig. 1 A and B,
arrows), in contrast to fenestrae described in the kidney,
pancreas, and brain. Their biological relevance in various
diseases has been widely acknowledged [3].
Evidence that VEGF-induced diaphragmed fenestrae
are derived from fused caveolae has recently been accu-
mulating. It has been postulated that a similar mechanism
is used in the formation of hepatic fenestrae. Conversely,
actin disruption in hepatic endothelial cells produces an
increase in the number of fenestrae by using a distinct
structure that appears to serve as a fenestrae-forming
center (Fig. 1C) [4]. Furthermore, it is important to em-
phasize the contradictions in the data reported about the
origin of fenestrae in kidney, pancreas, and in the liver.
For example, some data either clearly or indirectly indi-
cate a possible relationship between caveolae, vesiculo-
vacuolar organelles, and (diaphragmed) fenestrae; oth-
ers suggest the opposite (reviewed in [2]). Therefore,
until this controversy is settled, no firm conclusions can be
drawn, and stating that fenestrae, whether diaphragmed
or not, correspond to fused and interconnected caveolae
should be viewed with caution and remains as an emerg-
ing research topic.
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Braet and Soon question the conclusions we have
drawn in a recent review [1] about the relationship be-
tween caveolae and fenestrae in glomerular endothelium.
They suggest that we were too hasty in stating that fen-
estrae do not represent fused caveolae.
There is little doubt about the dynamic nature of fen-
estrae. Work with liver sinusoidal endothelial cells is
particularly interesting because these cells retain very
nice sieve plate structures in culture which can change
rapidly by alterations in actin microfilament dynamics
[2]. Also, VEGF-A can induce endothelial fenestration.
Conversely, interference with VEGF-A function in re-
nal glomeruli, for instance, in preeclampsia [3] or with
podocyte VEGF-A haploinsufficiency [4] leads to an ab-
sence of glomerular fenestrae. Finally, VEGF-A seems
to induce caveolin-1–containing vesicles to fuse and to
form transendothelial cell channels [5, 6]. Such circum-
stantial evidence has suggested that fenestrae represent
fused caveolae.
However, in caveolin-1–deficient mice known to lack
caveolae altogether [7], we found glomerular endothe-
lium with fenestrae that were normal in size and den-
sity, even though no caveolin-1 and no caveolae were
observed at all [8]. In normal rat glomeruli exam-
ined for caveolin-1 localization by immunogold elec-
tron microscopy, fenestrated portions of glomerular
